Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance?

Antibiotic resistance has increased over the past two decades. New approaches for the discovery of novel antibacterials are required and innovative strategies will be necessary to identify novel and effective candidates. Related to this problem, the exploration of bacterial targets that remain unexploited by the current antibiotics in clinical use is required. One of such targets is the $$\beta $$β-ketoacyl-acyl carrier protein synthase III (FabH). Here, we report a ligand-based modeling methodology for the virtual-screening of large collections of chemical compounds in the search of potential FabH inhibitors. QSAR models are developed for a diverse dataset of 296 FabH inhibitors using an in-house modeling framework. All models showed high fitting, robustness, and generalization capabilities. We further investigated the performance of the developed models in a virtual screening scenario. To carry out this investigation, we implemented a desirability-based algorithm for decoys selection that was shown effective in the selection of high quality decoys sets. Once the QSAR models were validated in the context of a virtual screening experiment their limitations arise. For this reason, we explored the potential of ensemble modeling to overcome the limitations associated to the use of single classifiers. Through a detailed evaluation of the virtual screening performance of ensemble models it was evidenced, for the first time to our knowledge, the benefits of this approach in a virtual screening scenario. From all the obtained results, we could arrive to a significant main conclusion: at least for FabH inhibitors, virtual screening performance is not guaranteed by predictive QSAR models.

[1]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[2]  Hong-Jia Zhang,et al.  Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors. , 2011, Bioorganic & medicinal chemistry.

[3]  Julie Clark,et al.  Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[4]  Yin Luo,et al.  Synthesis of C(7) modified chrysin derivatives designing to inhibit beta-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics. , 2009, Bioorganic & medicinal chemistry.

[5]  Simona Distinto,et al.  Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..

[6]  R. Heath,et al.  Roles of the FabA and FabZ β-Hydroxyacyl-Acyl Carrier Protein Dehydratases in Escherichia coli Fatty Acid Biosynthesis* , 1996, The Journal of Biological Chemistry.

[7]  A. Yan,et al.  Classification of Plasmodium falciparum glucose-6-phosphate dehydrogenase inhibitors by support vector machine , 2013, Molecular Diversity.

[8]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[9]  H. Nikaido Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.

[10]  Jin Chen,et al.  Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[11]  H. Yoneyama,et al.  Antibiotic Resistance in Bacteria and Its Future for Novel Antibiotic Development , 2006, Bioscience, biotechnology, and biochemistry.

[12]  R. Heath,et al.  Fatty acid biosynthesis as a target for novel antibacterials. , 2004, Current opinion in investigational drugs.

[13]  A. Sarai,et al.  Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM) , 2011, Molecular Diversity.

[14]  Xiao-Ming Wang,et al.  Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N'-phenyl-thiourea. , 2011, Bioorganic & medicinal chemistry.

[15]  Y. Castillo,et al.  Bacterial beta-ketoacyl-acyl carrier protein synthase III (FabH): an attractive target for the design of new broad-spectrum antimicrobial agents. , 2008, Mini reviews in medicinal chemistry.

[16]  R. Heath,et al.  Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein in Escherichia coli(*) , 1996, The Journal of Biological Chemistry.

[17]  K. Niihara,et al.  Synthesis of C , 2013 .

[18]  Alexander Golbraikh,et al.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2004, Molecular Diversity.

[19]  Shuai Zhang,et al.  Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. , 2012, Bioorganic & medicinal chemistry.

[20]  Nina Nikolova-Jeliazkova,et al.  QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.

[21]  Xiayang Qiu,et al.  First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. , 2003, Journal of medicinal chemistry.

[22]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[23]  S. Chirala,et al.  Human fatty acid synthase: properties and molecular cloning. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[25]  H Matter,et al.  Random or rational design? Evaluation of diverse compound subsets from chemical structure databases. , 1998, Journal of medicinal chemistry.

[26]  Ann Nowé,et al.  GA(M)E-QSAR: A Novel, Fully Automatic Genetic-Algorithm-(Meta)-Ensembles Approach for Binary Classification in Ligand-Based Drug Design , 2012, J. Chem. Inf. Model..

[27]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[28]  K. Reynolds,et al.  1,2-Dithiole-3-Ones as Potent Inhibitors of the Bacterial 3-Ketoacyl Acyl Carrier Protein Synthase III (FabH) , 2004, Antimicrobial Agents and Chemotherapy.

[29]  Yin Luo,et al.  Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents. , 2010, Bioorganic & medicinal chemistry letters.

[30]  Hong-Jia Zhang,et al.  Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents. , 2011, Bioorganic & medicinal chemistry.

[31]  Richard W. Hamming,et al.  Error detecting and error correcting codes , 1950 .

[32]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[33]  Fernanda Borges,et al.  Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors. , 2013, European journal of medicinal chemistry.

[34]  I. Tetko,et al.  ISIDA - Platform for Virtual Screening Based on Fragment and Pharmacophoric Descriptors , 2008 .

[35]  Ann Nowé,et al.  Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling , 2011, J. Comput. Aided Mol. Des..

[36]  S. Cho,et al.  HQSAR study of β-ketoacyl‐acyl carrier protein synthase III (FabH) inhibitors , 2007 .

[37]  R. Monaghan,et al.  Antibacterial drug discovery--then, now and the genomics future. , 2006, Biochemical pharmacology.

[38]  Yin Luo,et al.  Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[39]  Thomas J. Crisman,et al.  Which aspects of HTS are empirically correlated with downstream success? , 2008, Current opinion in drug discovery & development.

[40]  Kui Cheng,et al.  Design and synthesis of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents. , 2010, European journal of medicinal chemistry.

[41]  D. Moir,et al.  New classes of antibiotics. , 2012, Current opinion in pharmacology.

[42]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[43]  N. Waters,et al.  Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[44]  K. Gajiwala,et al.  Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents , 2005 .

[45]  Yan-Bin Zhang,et al.  Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[46]  Y. S. Prabhakar,et al.  QSAR studies on benzoylaminobenzoic acid derivatives as inhibitors of beta-ketoacyl-acyl carrier protein synthase III. , 2008, European journal of medicinal chemistry.